ClinicalTrials.gg
Not yet recruitingNCT07706010Updated Jul 15, 2026

Cardiovascular Risk in T2DM With MAFLD: A Cohort Study

An observational study in Type 2 Diabetes (T2DM) and Metabolic Dysfunction-Associated Steatotic Liver Disease, sponsored by The Affiliated Hospital of Hangzhou Normal University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by The Affiliated Hospital of Hangzhou Normal University · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
7,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
24th of 143
7,000 · median 556
Started
2026
with 88 others
Observational
143 of 913
56 open now
Primary completion
2028-05
later than 185 of 228 live
Registered
859th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 24th largest by planned enrollment of the 143 observational ones that give a count, is one of 89 that started in 2026, is one of 143 observational ones, reaches primary completion later than 185 of the 228 other live ones, and was the 859th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

This study aims to address the following key scientific question by establishing a large-scale, high-standard clinical cohort: the independent contribution of MASLD and its progression to liver fibrosis on cardiovascular outcomes in patients with T2DM, after excluding the confounding effects of traditional cardiovascular risk factors. Its technical value lies in utilizing prospective follow-up data combined with a multivariable competing risks model to develop and validate a cardiovascular risk prediction and early warning system tailored for Chinese populations with T2DM complicated by MASLD. Clinically, the findings will provide interdisciplinary evidence-based support for endocrinology and cardiology, helping clinicians identify high-risk individuals and prevent cardiovascular events through early intervention targeting hepatic metabolic disorders. This has significant implications for reducing overall mortality among diabetic patients in China and alleviating the public health burden.

03

Conditions studied

  • Type 2 Diabetes (T2DM)
  • Metabolic Dysfunction-Associated Steatotic Liver Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (≥18 years) with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease (MASLD) recruited from outpatient and inpatient departments of a tertiary hospital, who are able to complete long-term follow-up and provide informed consent.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1.Age ≥18 years, male or female;

    2.Meet the diagnostic criteria for type 2 diabetes mellitus (T2DM) according to the Chinese Guideline for the Prevention and Treatment of Type 2 Diabetes (2022 edition), with a confirmed diagnosis for at least 3 months;

    3.Meet the diagnostic criteria for metabolic dysfunction-associated steatotic liver disease (MASLD) according to the *Chinese Guideline for the Diagnosis and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (2024 edition)*, with preliminary assessment including liver enzymes (/AST), liver ultrasound, and non-invasive fibrosis markers (FIB-4, LSM), and exclusion of other liver diseases;

    4.Willing to participate in this study and provide written ;

    5.Able to cooperate with baseline survey and long-term follow-up (i.e., expected to reside in the study area during the follow-up period, without severe cognitive impairment, movement disorders, or other conditions that would interfere with follow-up).

Exclusion criteria

Exclusion Criteria:

  • 1.Concomitant other chronic liver diseases: viral hepatitis (, , etc.), alcoholic liver disease (alcohol intake ≥140 g/week for males, ≥70 g/week for females), liver disease, drug-induced liver injury, liver cirrhosis, liver cancer, etc.;

    2.Concomitant severe cardiovascular or cerebrovascular disease, end-stage renal disease (CKD stage 5), malignant tumor, severe infection, etc., with an estimated \<5 years;

    3.Current use of medications that may significantly affect liver metabolism or glucose metabolism (other than routine glucose-lowering, lipid-regulating, or hepatoprotective agents) that cannot be adjusted;

    4.Pregnant or lactating women, or those planning to become pregnant in the near term;

    5.Severe mental illness or cognitive impairment that prevents cooperation with surveys and follow-up;

    6.Refusal to sign , or inability to comply with study procedures.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
7,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • T2DM with MASLD and Low Fibrosis Burden

    Patients diagnosed with type 2 diabetes mellitus (T2DM) and metabolic dysfunction-associated steatotic liver disease (MASLD), with mild or no liver fibrosis (FIB-4 \<1.3 or liver stiffness measurement \[LSM\] \<8.0 kPa). Participants will receive routine clinical management and longitudinal follow-up.

  • T2DM with MASLD and Advanced Fibrosis

    Patients diagnosed with T2DM and MASLD who have significant liver fibrosis (FIB-4 ≥1.3 or LSM ≥8.0 kPa). Participants will receive routine clinical management and longitudinal follow-up.

06

What researchers measure

Primary outcomes

  1. Major Adverse Cardiovascular Events (MACE)

    The occurrence of major adverse cardiovascular events during the 5-year follow-up period, including: Cardiovascular death Non-fatal myocardial infarction Non-fatal ischemic or hemorrhagic stroke Hospitalization for heart failure

    Time frame: Baseline to 5 years

Secondary outcomes

  1. Progression of Liver Fibrosis

    Changes in liver fibrosis severity assessed by liver stiffness measurement (LSM), Fibrosis-4 index (FIB-4), and controlled attenuation parameter (CAP).

    Time frame: Every 12 months up to 5 years

  2. All-cause Mortality

    Death from any cause during follow-up.

    Time frame: Baseline to 5 years

  3. Renal Outcomes

    Development of end-stage kidney disease (ESKD), decline in estimated glomerular filtration rate (eGFR), or significant increase in urinary albumin-to-creatinine ratio (UACR).

    Time frame: Time Frame: Baseline to 5 years

  4. Cardiovascular Imaging Progression

    Changes in carotid intima-media thickness (CIMT), carotid plaque burden, left ventricular structure and function, and coronary artery stenosis.

    Time frame: Annually for 5 years

  5. Liver-related Clinical Outcomes

    Development of cirrhosis, hepatocellular carcinoma, liver failure, or liver-related death.

    Time frame: Baseline to 5 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for May 2028, 22 months later.

Of 436 non-industry observational studies under Diabetes Mellitus, Type 2, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 96. This study's planned 22 months is below that.

Counting every sponsor, half of 606 studies reached it within 32 months; a quarter within 17 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2026
First posted
Jul 15, 2026
StartEst.
Jul 12, 2026
Primary completionEst.
May 29, 2028
CompletionEst.
May 29, 2031
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07706010
Lead sponsor
The Affiliated Hospital of Hangzhou Normal University
Responsible party
Sponsor
First posted
Jul 15, 2026
Start date
Jul 12, 2026 (estimated)
Primary completion
May 29, 2028 (estimated)
Completion
May 29, 2031 (estimated)
Last update
Jul 15, 2026

Study contacts

Mingwei W Wang, PhD
Contact
wmw990556@163.com
18758871517 ext. not

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion